ADMA Biologics FY24 revenue $426.5M (+65% YoY); raises FY25/26 guidance

ADMA BIOLOGICS, INC.

FY 2024 total revenue $426.5M (+65% YoY); GAAP net income $197.7M incl. $84.3M tax benefit; Adjusted EBITDA $164.6M (+309% YoY).
Q4 2024 revenue $117.5M (+59% YoY); GAAP net income $111.9M vs net loss of $17.6M; Adjusted EBITDA $48.3M vs $18.6M.
FY 2025 revenue guidance raised to >$490M; FY 2026 >$605M; expects >$1B total revenue before 2030.
FDA approval of yield enhancement process expected mid-2025, potentially increasing IG yields ~20%; long-term plasma supply from ~250 centers.
Form 10-K filing delayed to on or before March 18, 2025 due to need for additional time to test internal controls with KPMG.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.